TipRanks on MSN

Incyte steps into late-stage colorectal cancer race with new phase 3 trial of INCA33890

Incyte ($INCY) announced an update on their ongoing clinical study. Study Overview Incyte’s new Phase 3 trial, titled “A Randomized, Double-Blind, ...
TipRanks on MSN

BMY and BNTX advance new immunotherapy bet in first-line liver cancer with ROSETTA HCC-206

Biontech Se Sponsored Adr (BNTX), Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study.
Targeted Oncology

Illuminating the Sequence of Third-Line Therapies in Metastatic CRC

The patient received trifluridine/tipiracil plus bevacizumab as third-line therapy; is currently on month 4 of treatment.​ ...
Endocrinology Advisor

Adding Atezolizumab to Standard Therapy Fails to Improve Survival in Recurrent Ovarian Cancer

Atezolizumab plus standard therapy was not associated with improved survival in advanced recurrent ovarian cancer.

CytomX: Easiest Money May Have Been Made, Although Pipeline Remains Compelling

CytomX has confirmed a Q1'26 readout for additional data from its trial of CX-2051 in colorectal cancer. Read why CTMX stock ...